DMTK vs. RNLX, XGN, PMD, BGLC, FRES, OPGN, ACON, NVTA, CNTG, and ENZ
Should you be buying DermTech stock or one of its competitors? The main competitors of DermTech include Renalytix (RNLX), Exagen (XGN), Psychemedics (PMD), BioNexus Gene Lab (BGLC), Fresh2 Group (FRES), OpGen (OPGN), Aclarion (ACON), Invitae (NVTA), Centogene (CNTG), and Enzo Biochem (ENZ). These companies are all part of the "medical laboratories" industry.
Renalytix (NASDAQ:RNLX) and DermTech (NASDAQ:DMTK) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.
In the previous week, DermTech's average media sentiment score of 0.00 equaled Renalytix'saverage media sentiment score.
Renalytix has higher earnings, but lower revenue than DermTech. Renalytix is trading at a lower price-to-earnings ratio than DermTech, indicating that it is currently the more affordable of the two stocks.
DermTech received 38 more outperform votes than Renalytix when rated by MarketBeat users. Likewise, 57.50% of users gave DermTech an outperform vote while only 32.00% of users gave Renalytix an outperform vote.
DermTech has a net margin of -572.19% compared to DermTech's net margin of -1,687.80%. Renalytix's return on equity of -138.79% beat DermTech's return on equity.
Renalytix presently has a consensus price target of $5.00, suggesting a potential upside of 1,008.65%. DermTech has a consensus price target of $2.38, suggesting a potential upside of 602.12%. Given DermTech's stronger consensus rating and higher possible upside, research analysts clearly believe Renalytix is more favorable than DermTech.
Renalytix has a beta of 2.88, meaning that its share price is 188% more volatile than the S&P 500. Comparatively, DermTech has a beta of 2.48, meaning that its share price is 148% more volatile than the S&P 500.
9.9% of Renalytix shares are held by institutional investors. Comparatively, 20.5% of DermTech shares are held by institutional investors. 18.3% of Renalytix shares are held by insiders. Comparatively, 5.1% of DermTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Renalytix and DermTech tied by winning 8 of the 16 factors compared between the two stocks.
Get DermTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for DMTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DMTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DermTech Competitors List
Related Companies and Tools
